The University of Southampton
University of Southampton Institutional Repository

Use of hormonal contraceptive methods by women with diabetes

Use of hormonal contraceptive methods by women with diabetes
Use of hormonal contraceptive methods by women with diabetes
Background and methodology

This study sought to establish use of hormonal contraception in UK women aged between 15 and 44 years with type 1 or type 2 diabetes compared with comparison groups with no diabetes. A cross sectional study design was used to compare 947 cases of type 1 diabetes and 365 cases of type 2 diabetes with comparison groups matched for age. Subjects were selected from the General Practice Research Database (GPRD).
Results

Women with diabetes were less likely to use hormonal contraception than women without diabetes – type 1 RR 0.83 (95% CI 0.59–0.93), type 2 RR 0.60 (95% CI 0.42–0.83). Women with type 1 diabetes were more likely to be prescribed a combined pill than a progestogen only pill (POP), but were significantly more likely to be prescribed the POP than were women without diabetes RR 1.65 (95% CI 1.26–2.13). Women with type 2 diabetes were less likely to be prescribed a combined oral contraceptive RR 0.39 (95% CI 0.24–0.62). The injectable contraceptive Depo Provera was significantly more likely to be given to women with diabetes than the comparison group – type 1 RR 1.56 (95% CI 1.12–2.11), type 2 RR 3.57 (95% CI 2.15–5.60).
Discussion and conclusions

The study highlighted significant variation in prescribing of hormonal contraception to women with type 1 and type 2 diabetes in comparison to those without diabetes. It is now recognised that hormonal contraception is a safe and effective option for women with uncomplicated diabetes. Possibly there are significant numbers of young women with poorly controlled diabetes or other risk factors for cardiovascular disease that have influenced clinicians in avoiding the use of hormonal contraception. Paradoxically it is these women who are at most risk from unplanned pregnancy.
1751-9918
195-199
Shawe, Jill
b205d36d-623c-47c1-88ce-598b918c523e
Mulnier, Henrietta
58546f2e-ffdb-4951-8fa4-0759b9ffbe84
Nicholls, Peter
18255e5f-5086-4cc5-bf75-d6aad9ee51d9
Lawrensond, Ross
959a600f-3a23-40e8-8aaf-25af1e6b73bf
Shawe, Jill
b205d36d-623c-47c1-88ce-598b918c523e
Mulnier, Henrietta
58546f2e-ffdb-4951-8fa4-0759b9ffbe84
Nicholls, Peter
18255e5f-5086-4cc5-bf75-d6aad9ee51d9
Lawrensond, Ross
959a600f-3a23-40e8-8aaf-25af1e6b73bf

Shawe, Jill, Mulnier, Henrietta, Nicholls, Peter and Lawrensond, Ross (2008) Use of hormonal contraceptive methods by women with diabetes. Primary Care Diabetes, 2 (4), 195-199. (doi:10.1016/j.pcd.2008.10.003). (PMID:19019754)

Record type: Article

Abstract

Background and methodology

This study sought to establish use of hormonal contraception in UK women aged between 15 and 44 years with type 1 or type 2 diabetes compared with comparison groups with no diabetes. A cross sectional study design was used to compare 947 cases of type 1 diabetes and 365 cases of type 2 diabetes with comparison groups matched for age. Subjects were selected from the General Practice Research Database (GPRD).
Results

Women with diabetes were less likely to use hormonal contraception than women without diabetes – type 1 RR 0.83 (95% CI 0.59–0.93), type 2 RR 0.60 (95% CI 0.42–0.83). Women with type 1 diabetes were more likely to be prescribed a combined pill than a progestogen only pill (POP), but were significantly more likely to be prescribed the POP than were women without diabetes RR 1.65 (95% CI 1.26–2.13). Women with type 2 diabetes were less likely to be prescribed a combined oral contraceptive RR 0.39 (95% CI 0.24–0.62). The injectable contraceptive Depo Provera was significantly more likely to be given to women with diabetes than the comparison group – type 1 RR 1.56 (95% CI 1.12–2.11), type 2 RR 3.57 (95% CI 2.15–5.60).
Discussion and conclusions

The study highlighted significant variation in prescribing of hormonal contraception to women with type 1 and type 2 diabetes in comparison to those without diabetes. It is now recognised that hormonal contraception is a safe and effective option for women with uncomplicated diabetes. Possibly there are significant numbers of young women with poorly controlled diabetes or other risk factors for cardiovascular disease that have influenced clinicians in avoiding the use of hormonal contraception. Paradoxically it is these women who are at most risk from unplanned pregnancy.

This record has no associated files available for download.

More information

Published date: December 2008

Identifiers

Local EPrints ID: 162231
URI: http://eprints.soton.ac.uk/id/eprint/162231
ISSN: 1751-9918
PURE UUID: 1926dbe0-8a17-4dbc-8682-fd295dde8e3e

Catalogue record

Date deposited: 17 Aug 2010 14:18
Last modified: 14 Mar 2024 02:01

Export record

Altmetrics

Contributors

Author: Jill Shawe
Author: Henrietta Mulnier
Author: Peter Nicholls
Author: Ross Lawrensond

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×